According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
Other equities research analysts have also recently issued reports about the stock. Jefferies Group dropped their price target on shares of MediWound from $15.00 to $13.00 and set a buy rating on the stock in a research report on Friday, July 29th. Wells Fargo & Co. began coverage on shares of MediWound in a research report on Wednesday, August 17th. They issued an outperform rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. MediWound has an average rating of Buy and a consensus target price of $13.63.
MediWound (NASDAQ:MDWD) remained flat at $7.46 during trading on Wednesday. 1 shares of the stock were exchanged. The firm’s market cap is $163.00 million. MediWound has a one year low of $5.66 and a one year high of $10.47. The company’s 50 day moving average price is $7.71 and its 200-day moving average price is $7.79.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.11. MediWound had a negative return on equity of 103.14% and a negative net margin of 2,332.07%. The business earned $3.36 million during the quarter, compared to the consensus estimate of $0.45 million. During the same quarter last year, the firm posted ($0.19) earnings per share. MediWound’s revenue was up 115.8% compared to the same quarter last year. Equities analysts predict that MediWound will post ($1.02) earnings per share for the current year.
Several institutional investors have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of MediWound during the second quarter valued at approximately $13,302,000. Wellington Management Group LLP boosted its stake in shares of MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock valued at $8,431,000 after buying an additional 100,723 shares during the last quarter. United Services Automobile Association boosted its stake in shares of MediWound by 125.9% in the second quarter. United Services Automobile Association now owns 123,440 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 68,800 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of MediWound by 19.4% in the first quarter. Renaissance Technologies LLC now owns 49,800 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 8,100 shares during the last quarter. Institutional investors own 26.48% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.